相关实验视频

Updated: Sep 18, 2025

Non-chromatographic Purification of Recombinant Elastin-like Polypeptides and their Fusions with Peptides and Proteins from Escherichia coli
07:35

Non-chromatographic Purification of Recombinant Elastin-like Polypeptides and their Fusions with Peptides and Proteins from Escherichia coli

Published on: June 9, 2014

21.9K

对于elacestrant二化的新型多态模式

Zia Uddin Masum1, P Grant Spoors2, Matt D Burke2

  • 1Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, 8000 Utopia Parkway, Queens, NY 11439, USA.

Pharmaceutics
|June 27, 2025
PubMed
概括

这项研究确定了elacestrant二化的六种新的晶体模式,扩大了其已知的多态性. 模式A,C和E显示出进一步开发和大规模生产的前景.

关键词:
没有形状的无形.添加了抗溶剂的抗溶剂添加剂.标志性特征的描述.结晶的 结晶的这是一个严格的限制.聚合物模板的模板设计多形态主义的多态主义.溶剂滴滴研磨 溶剂滴滴研磨 是一种

更多相关视频

A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients11:27

A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients

Published on: August 9, 2022

2.2K
Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles07:32

Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles

Published on: August 28, 2015

11.4K

相关概念视频

Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism01:21

Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism

Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
406
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
312